pomalidomide
Selected indexed studies
- Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. (Lancet Oncol, 2021) [PMID:34087126]
- Pomalidomide. (Recent Results Cancer Res, 2014) [PMID:24756804]
- Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia. (N Engl J Med, 2024) [PMID:39292928]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. (2023) pubmed
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. (2019) pubmed
- Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. (2021) pubmed
- Pomalidomide. (2014) pubmed
- Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia. (2024) pubmed
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. (2019) pubmed
- Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis. (2024) pubmed
- Pomalidomide. (2018) pubmed
- Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial. (2023) pubmed
- Pomalidomide. (2013) pubmed